AZN
AstraZeneca ADR
AstraZeneca plc () is a British (formely British-Swedish) multinational pharmaceutical and biopharmaceutical company with its global headquarters in Cambridge, United Kingdom. Its R&D is concentrated in Cambridge in United Kingdom, Södertälje in Sweden, and Maryland and Toronto in North America. AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation.The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). Since the merger it has been among the world’s largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
AstraZeneca has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. It has secondary listings on the Nasdaq, the Bombay Stock Exchange, National Stock Exchange of India and the OMX exchange.
Index: NYSE; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 143.96B; Volume: 652.47K; AvgVol 3m: 6.42M; Beta: 0.53;
Cost estimate:
P/E: 66.22; EPS: 0.82; EPS growth quarter/prev quarter: 481.10%;
EPS growth this year: -39.70%; EPS growth past 5 years: 1.00%;
EPS ttm: 0.82;
P/S: 5.54; P/B: 11.53; P/Cashflow: 23.28; P/FCF: ;
Sales: 25.70B; Sales growth quarter/prev quarter: 7.80%; Sales growth past 5 years: -1.70%;
Profitability:
Gross Margin: 80.30%; Profit Margin: 8.40%; Operating Margin: 14.90%;
ROA – return on assets: 3.60%; ROE – return on equity: 17.80%; LT Debt/Equity: 1.28; Total Debt/Equity: 1.61;
Dividend: 1.40; Dividend Yield (%): 2.58%;
Insider Ownership: 0.50%; Insider Transactions:0.00%;
Institutional Ownership: 17.60%; Institutional Transactions: -3.50%;
Data update: 07/10/2020.